10th International Congress on Drug Therapy in HIV Infection, 7-11 November 2010, Glasgow
1 December 2010. Related: Conference reports.
HIV 10 Glasgow 2010
Virological findings from the SARA trial ofboosted protease inhibitor monotherapy
1 December 2010. Related: Conference reports, Antiretrovirals, Treatment access, Virology.
Nevirapine exposure was not associated with hypersensitivity in patients from Malawi
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Estimating the number of people in a country or region with HIV who are undiagnosed and in need of ART
1 December 2010. Related: Conference reports, Antiretrovirals.
Highpreterm delivery rates associated with initiation of HAART during pregnancy at a London clinic
1 December 2010. Related: Conference reports, Pregnancy.
Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy
1 December 2010. Related: Conference reports, Pregnancy, Drug resistance.
The Antiretroviral Pregnancy Registry reports no increased rate of birth defects with atazanavir exposure
1 December 2010. Related: Conference reports, Pregnancy.
Pharmacokinetics of lopinavir/ritonavir incombination with rifampicin based TB treatment in children
1 December 2010. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Efavirenz versus nevirapine based first linetreatment in a South African cohort
1 December 2010. Related: Conference reports, Antiretrovirals, Pregnancy.
GSK572: 24-week results in treatment-naive and raltegravir-experienced patients
1 December 2010. Related: Conference reports, Antiretrovirals.
Consensus guidelines recommend routine use of genotypic tropism testing: new focus on maraviroc as a switching option (2010)
1 December 2010. Related: Conference reports, Antiretrovirals, Guidelines.
UK studies on bone health: increasedfracture rates reported in HIV-positive people
1 December 2010. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Muscle weakness or pain analysed as possible raltegravir side effect
1 December 2010. Related: Conference reports, Antiretrovirals, Side effects.
Adding maraviroc does not boost CD4s inrandomised trial
1 December 2010. Related: Conference reports, Antiretrovirals.
Switch to twice-daily unboosted atazanavir outdoes switch to once-daily dose
1 December 2010. Related: Conference reports, Antiretrovirals.